Nature World News reports that the U.S. Food and Drug Administration has approved the anti-cholesterol drug Liptruzet.
According to the story, Liptruzet is a combination of Merck’s Zetia, which lowers low-density lipoprotein (LDL), and a generic version of Pfizer’s Lipitor, which lost its patent protection in 2011.
Lipitor has recently generated some health concerns.
The U.S. Food and Drug Administration has added warnings to Lipitor’s label, advising that the medication may increase the ...
continue reading...